Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.

MLA

Zhong, Qiaofeng, et al. “Development and Validation of a Novel Risk Stratification Model and a Survival Rate Calculator for Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multi-Institutional Cohort Study.” Annals of Hematology, vol. 103, no. 1, Jan. 2024, pp. 211–26. EBSCOhost, https://doi.org/10.1007/s00277-023-05491-0.

APA

Zhong, Q., Chen, H., Chen, D., Qin, Y., He, X., Yang, Y., Yang, J., Liu, P., Zhou, S., Yang, S., Zhou, Y., Tang, L., Chen, C., & Shi, Y. (2024). Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. Annals of Hematology, 103(1), 211–226. https://doi.org/10.1007/s00277-023-05491-0

Chicago

Zhong, Qiaofeng, Haizhu Chen, Daoguang Chen, Yan Qin, Xiaohui He, Yu Yang, Jianliang Yang, et al. 2024. “Development and Validation of a Novel Risk Stratification Model and a Survival Rate Calculator for Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multi-Institutional Cohort Study.” Annals of Hematology 103 (1): 211–26. doi:10.1007/s00277-023-05491-0.